RecruitingPhase 2NCT03984565

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product


Sponsor

Staci Gruber, Ph.D.

Enrollment

25 participants

Start Date

Jun 27, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.


Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cannabidiol and a drug called Placebo for people with chronic pain. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabidiol

High-CBD, low-THC sublingual product formulated in palm oil

DRUGPlacebo

Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.


Locations(1)

McLean Hospital

Belmont, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03984565


Related Trials